Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2022

21-10-2021 | Hepatic Encephalopathy | Original Article

Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications

Authors: Daniel A. Burkholder, Isabel J. Moran, Jacob V. DiBattista, Anna S. Lok, Neehar D. Parikh, Vincent L. Chen

Published in: Digestive Diseases and Sciences | Issue 8/2022

Login to get access

Abstract

Background and Aims

International Classification of Diseases (ICD)-10 codes may correspond to cirrhosis diagnosis. However, these codes have not been as well studied as ICD-9 codes. We aimed to evaluate the positive predictive value (PPV) and specificity of ICD-10 codes for cirrhosis.

Methods

We conducted a single-center retrospective study of patients in Michigan Medicine (Ann Arbor, MI, USA). We evaluated patients with at least one of 28 ICD-10 codes for cirrhosis and randomly selected controls for the presence of cirrhosis and/or portal hypertensive complications.

Results

Among 1317 patients with at least one ICD-10 code consistent with cirrhosis and/or portal hypertension, 796 had confirmed cirrhosis. After excluding ICD-10 codes found in < 10 patients, we evaluated the PPV of the 19 remaining codes. Of these, 15 had a high PPV for cirrhosis (> 80%), including codes for cirrhosis itself, gastroesophageal varices, hepatic encephalopathy, and other portal hypertensive complications. Specificity of ICD codes for cirrhosis for these 15 codes was high (> 94% for all). PPV and specificity were high across liver disease etiologies. Among patients without portal hypertension, PPVs of ICD-10 codes for cirrhosis were lower but still > 80% for the most common codes. PPVs of most codes for portal hypertensive complications were > 70%. Defining cirrhosis based on the presence of any of the 15 codes resulted in a PPV of 86% and by two different codes, a PPV 94%.

Conclusions

ICD-10 codes for cirrhosis can accurately identify patients with cirrhosis with or without portal hypertensive complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Asrani S, Devarbhavi H, Eaton J, Kamath P. Burden of liver diseases in the world. J Hepatol. 2019;70:151–171.CrossRef Asrani S, Devarbhavi H, Eaton J, Kamath P. Burden of liver diseases in the world. J Hepatol. 2019;70:151–171.CrossRef
2.
go back to reference Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442–5460.CrossRef Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442–5460.CrossRef
3.
go back to reference Roth GA, Abate D, Abate KH et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392:1736–1788.CrossRef Roth GA, Abate D, Abate KH et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392:1736–1788.CrossRef
4.
go back to reference Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149:1471–1482 e1475; quiz e1417–1478. Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149:1471–1482 e1475; quiz e1417–1478.
5.
go back to reference Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2:288–297.CrossRef Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol. 2017;2:288–297.CrossRef
6.
go back to reference Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017–2018. J Gen Intern Med. 2021. Kim D, Cholankeril G, Loomba R, Ahmed A. Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017–2018. J Gen Intern Med. 2021.
7.
go back to reference Scaglione S, Kliethermes S, Cao G et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49:690–696.CrossRef Scaglione S, Kliethermes S, Cao G et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49:690–696.CrossRef
8.
go back to reference Mellinger JL, Shedden K, Winder GS et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68:872–882.CrossRef Mellinger JL, Shedden K, Winder GS et al. The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology. 2018;68:872–882.CrossRef
9.
go back to reference Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;362:k2817. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ. 2018;362:k2817.
10.
go back to reference Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.
11.
go back to reference Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Netw Open. 2020;3:e201997. Hirode G, Saab S, Wong RJ. Trends in the Burden of Chronic Liver Disease Among Hospitalized US Adults. JAMA Netw Open. 2020;3:e201997.
12.
go back to reference Organization WH. The International Statistical Classification of Diseases and Health Related Problems ICD-10: Tenth Revision. Volume 1: Tabular List. Vol 1: World Health Organization; 2004. Organization WH. The International Statistical Classification of Diseases and Health Related Problems ICD-10: Tenth Revision. Volume 1: Tabular List. Vol 1: World Health Organization; 2004.
13.
go back to reference Hayward KL, Johnson AL, McKillen BJ, et al. ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies. BMJ Open Gastroenterol. 2020;7. Hayward KL, Johnson AL, McKillen BJ, et al. ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies. BMJ Open Gastroenterol. 2020;7.
14.
go back to reference Utter GH, Atolagbe OO, Cooke DT. The use of the international classification of diseases, tenth revision, clinical modification and procedure classification system in clinical and health services research: the devil is in the details. JAMA Surg. 2019;154:1089–1090.CrossRef Utter GH, Atolagbe OO, Cooke DT. The use of the international classification of diseases, tenth revision, clinical modification and procedure classification system in clinical and health services research: the devil is in the details. JAMA Surg. 2019;154:1089–1090.CrossRef
15.
go back to reference Nehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of administrative claims data for identifying patients with cirrhosis. Journal of clinical gastroenterology. 2013;47:e50–e54.CrossRef Nehra MS, Ma Y, Clark C, Amarasingham R, Rockey DC, Singal AG. Use of administrative claims data for identifying patients with cirrhosis. Journal of clinical gastroenterology. 2013;47:e50–e54.CrossRef
16.
go back to reference Goldberg D, Lewis J, Halpern S, Weiner M, Lo Re V. 3rd. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf. 2012;21:765–769.CrossRef Goldberg D, Lewis J, Halpern S, Weiner M, Lo Re V. 3rd. Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf. 2012;21:765–769.CrossRef
17.
go back to reference Bengtsson B, Askling J, Ludvigsson JF, Hagstrom H. Validity of administrative codes associated with cirrhosis in Sweden. Scand J Gastroenterol. 2020;55:1205–1210.CrossRef Bengtsson B, Askling J, Ludvigsson JF, Hagstrom H. Validity of administrative codes associated with cirrhosis in Sweden. Scand J Gastroenterol. 2020;55:1205–1210.CrossRef
18.
go back to reference Ramrakhiani NS, Le MH, Yeo YH, Le AK, Maeda M, Nguyen MH. Validity of International Classification of Diseases, 10th Revision, Codes for Cirrhosis. Digestive Diseases. 2020. Ramrakhiani NS, Le MH, Yeo YH, Le AK, Maeda M, Nguyen MH. Validity of International Classification of Diseases, 10th Revision, Codes for Cirrhosis. Digestive Diseases. 2020.
19.
go back to reference Mapakshi S, Kramer JR, Richardson P, El-Serag HB, Kanwal F. Positive predictive value of international classification of diseases, 10th revision, codes for cirrhosis and its related complications. Clin Gastroenterol Hepatol. 2018;16:1677–1678.CrossRef Mapakshi S, Kramer JR, Richardson P, El-Serag HB, Kanwal F. Positive predictive value of international classification of diseases, 10th revision, codes for cirrhosis and its related complications. Clin Gastroenterol Hepatol. 2018;16:1677–1678.CrossRef
20.
go back to reference Chen VL, Chen Y, Du X, Handelman SK, Speliotes EK. Genetic variants that associate with cirrhosis have pleiotropic effects on human traits. Liver International. 2019;40:405–415.CrossRef Chen VL, Chen Y, Du X, Handelman SK, Speliotes EK. Genetic variants that associate with cirrhosis have pleiotropic effects on human traits. Liver International. 2019;40:405–415.CrossRef
21.
go back to reference Lapointe-Shaw L, Georgie F, Carlone D, et al. Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study. PLoS One. 2018;13:e0201120. Lapointe-Shaw L, Georgie F, Carlone D, et al. Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study. PLoS One. 2018;13:e0201120.
22.
go back to reference Collett D. Modelling Binary Data, Second Edition. Taylor & Francis; 2002. Collett D. Modelling Binary Data, Second Edition. Taylor & Francis; 2002.
Metadata
Title
Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications
Authors
Daniel A. Burkholder
Isabel J. Moran
Jacob V. DiBattista
Anna S. Lok
Neehar D. Parikh
Vincent L. Chen
Publication date
21-10-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07282-x

Other articles of this Issue 8/2022

Digestive Diseases and Sciences 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.